The FDA has approved a new indication for the diabetes drug empagliflozin to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease.
The Centers for Disease Control and Prevention has reported that cardiovascular disease deaths are about 70% higher among adults with diabetes compared with those who don’t have the illness. “Availability of antidiabetes therapies that can help people live longer by reducing the risk of cardiovascular death is an important advance for adults with type 2 diabetes,” Jean-Marc Guettier, MD, director of the FDA’s Division of Metabolism and Endocrinology Products, said in a statement.
Voelker R. Diabetes Drug Gains New Indication. JAMA. 2017;317(3):247. doi:10.1001/jama.2016.19774
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: